Related Experiment Video
Updated: Dec 31, 2025
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma
Yi Wang1, Weirong Qin, Hongdong Shi
1Key Laboratory for Advanced Materials of MOE, School of Chemistry & Molecular Engineering, East China University of Science and Technology, Shanghai, 200237, P. R. China. liujingang@ecust.edu.cn.
Abstract:
An HCBP1 peptide-ruthenium conjugate (Ru-β-Ala-FQHPSFI) as a potential candidate for targeted therapy of hepatoma was synthesized. Ru-β-Ala-FQHPSFI shows drastically enhanced cytotoxicity and high selectivity for hepatoma cells versus noncancer liver cells. Raman imaging shows that this peptide-based drug can be taken up well by the hepatoma cells compared with the bare ruthenium complex (Ru) and the opposite sequence peptide-ruthenium conjugate (Ru-β-Ala-IFSPHQF). This study presents a new strategy for the construction of tumor-targeting metal-based anticancer therapeutics.
More Related Videos
09:12Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
Published on: May 11, 2018
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
